An app uses blood sugar readings and other diabetes information to provide personalized guidance to workouts, along with exercise videos specifically for people with...

An innovative program in Houston empowers members of faith communities to lead diabetes education, peer support, and prevention efforts in their communities

A new study is investigating whether higher doses of injectable GLP-1 agonist Trulicity (dulaglutide) are more effective; it is recruiting 1,800 participants with type 2...

A unique mindset to resist tempting foods, including in peer-pressured group settings

A study testing whether One Drop’s coaching app, along with Fitbit activity trackers, can help people with diabetes and prediabetes meet their goals

Two new studies will investigate whether SGLT-2 inhibitor Jardiance impacts heart failure in people with and without diabetes. Jardiance is already approved to lower A1C...

Acclaimed author James S. Hirsch on his encounter with a broken healthcare system while trying to obtain FreeStyle Libre for his teenage son

Learn what heart failure is, what it has to do with diabetes, and how to identify and talk about this complication that’s often less discussed.

Dexcom G6 cleared by FDA with no fingerstick calibrations, 10-day wear time, approval for ages 2 years and older, no acetaminophen interference, and more

Phase 3 clinical trial currently recruiting 400 adults with type 2 diabetes

Admelog is Sanofi’s version of Humalog (insulin lispro). New prescription savings card is for both Admelog and Lantus for people who would otherwise need to pay full...

Adults with type 1 and type 2 can now choose Fiasp, which can be taken up to 20 minutes after starting a meal and still be effective

Simple steps you can take to reduce your risk for heart failure. Plus, how to work with your health professional to manage it once you’ve been diagnosed.

Recruiting 1,200 people with type 2 diabetes from diverse ethnic and racial backgrounds for a more thorough understanding of Soliqua’s impact on diabetes management

The results were so positive it was deemed unethical to keep giving people placebo instead of Invokana, an SGLT-2 inhibitor approved for type 2 diabetes

FDA clearance and limited US launch expected in the second half of 2018. Dash adds improved user experience, Bluetooth, smartphone viewing, remote monitoring

A positive 8-0 vote at the FDA paves the way for first implanted CGM to come to the US; read what patient advocates and healthcare providers like about Eversense!

Healthcare professionals are increasingly recognizing peer support as a valuable element of diabetes care; read for a list of peer support communities

App allows FreeStyle Libre sensor users to monitor blood sugar on their smartphone without a separate reader. Tools also available for sharing glucose data with...

Limited launch in May-July. No receiver! Smartphone-only display on Apple iOS devices. Plus, the new “personal diabetes assistant,” Sugar.IQ with Watson